Study: 4 reassortant H7N9 strains circulating in Chinese province
Sequence analysis of human and environmental samples demonstrated that four strains of reassorted H7N9 avian flu viruses have been circulating in Guangdong province—one of the country's hardest hit—and that an increase of human cases last year coincided with an increase in H7 isolates in environmental samples, according to a study today in Emerging Infectious Diseases.
Researchers from the Guangdong Provincial Center for Disease Control and Prevention, as well as Ron Fouchier, PhD, and Marion Koopmans, DVM, PhD, of Erasmus Medical Center in the Netherlands, analyzed data from 8,942 environmental samples taken from poultry markets in 21 cities from Apr 15, 2013, through Feb 28, 2014. Of those, 425 samples (4.8%) from 13 cities tested positive for H7 viruses, and 1,050 (11.8%) from 19 cities were positive for H9 viruses.
The team also analyzed data from 34,342 samples from patients with pneumonia or flu-like illness from 21 cities from April 2013 through February 2014. Of those, samples from 81 patients in 10 cities tested positive for H7N9. All but 6 of the cases were confirmed in early 2014.
Sequence analysis showed co-circulation of four distinct H7N9 strains that evolved by reassortment with H9N2 avian flu viruses circulating in the province, the authors wrote. They also found that an increase in human cases starting in late 2013 coincided with an increase in H7 virus isolates detected by environmental surveillance.
The authors conclude, "Co-circulation of multiple avian influenza viruses that can infect humans highlights the need for increased surveillance of poultry and potential environmental sources."
Aug 27 Emerg Infect Dis study
Study: Flu vaccine against unfamiliar strain may induce broad protection
US researchers say they have found that giving people a flu vaccine targeting an unfamiliar flu strain—H5N1 avian flu, in this case—may be a good way to generate antibodies targeting the stem of the flu virus's hemagglutinin (HA) protein, a structure that is a major focus of efforts to develop a "universal" or broadly protective flu vaccine.
The HA head, the part most visible to the immune system, mutates frequently, requiring yearly reformulation of flu vaccines to keep up with circulating flu strains. In contrast, the stem is relatively stable, and it is believed that a vaccine that generates antibodies to the stem might provide protection against a number of different strains.
In the study, published in the Proceedings of the National Academy of Sciences, researchers with the Emory Vaccine Center found that people vaccinated against H5N1, to which the US population has not been exposed, developed antibodies against the HA stem. Those who received a regular trivalent seasonal flu vaccine, however, developed antibodies mainly against the HA head.
In an Emory press release, lead author Ali Ellebedy, PhD, said the key to having volunteers' bodies produce antibodies against the stem region seemed to be their immune systems' unfamiliarity with the H5N1 virus.
In 2009, Emory researchers found that several patients infected with the 2009 H1N1 pandemic flu strain developed broadly cross-reactive antibodies, according to the release. At the time, most young adults had never been exposed to that strain.
In the current study, the team analyzed levels of antibody against different parts of the HA in 17 volunteers before and after H5N1 vaccination, the release explains. Anti-stem antibody levels rose an average of fourfold after the first H5N1 vaccination. But after an H5N1 booster shot, anti-head responses dominated while anti-stem responses were feeble.
The authors say their data also show that antibodies and memory B cells directed against the HA stem region are prevalent in humans, but at levels much lower than B-cell responses directed to the HA head.
"Our findings delineate a potential vaccination strategy where H5N1 or H7N9 immunization could be used not only for immunologically priming the population to quickly respond to serious pandemic influenza threats, but also for generating broadly neutralizing antibodies against influenza in humans," the report concludes.
Aug 25 Proc Natl Acad Sci abstract
Aug 25 Emory press release